CEO of Cosmos Health Boosts His Shareholding Significantly
In a notable move reflecting his confidence in the company’s future, Greg Siokas, the CEO of Cosmos Health Inc., has recently acquired 1,466,764 shares valued at approximately $526,000. This series of transactions performed between April 21 and April 24 marks a substantial increase in his total ownership stake in the innovative healthcare corporation.
Building on a Strong Foundation
Following this acquisition, Mr. Siokas has increased his overall shares in Cosmos Health to a total of 5,582,066. This proactive investment showcases his ongoing commitment to the company's growth strategy and speaks volumes about his belief in Cosmos Health’s market position.
The Financial Commitment Over Time
In just the last five months, Mr. Siokas has invested over $1.3 million to acquire more than 2.7 million shares. His total investment since the beginning now exceeds $18 million, underscoring a deep-seated belief in the long-term potential of Cosmos Health. Through his leadership, he aims to navigate the company towards innovative horizons and deliver substantial value to shareholders.
Words from the CEO
Expressing his enthusiasm and confidence, Greg Siokas stated, "I am proud of what we have accomplished in building a diversified, vertically integrated global healthcare company, and I am even more excited about the opportunities that lie ahead." This statement resonates with many stakeholders, highlighting a narrative of growth and innovation amid a dynamic healthcare landscape.
About Cosmos Health Inc.
Founded in 2009 and incorporated in Nevada, Cosmos Health Inc. stands as a diversified entity within the global healthcare sector. The company boasts an impressive portfolio of proprietary pharmaceutical and nutraceutical brands, which include Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. With a robust manufacturing background through its subsidiary, Cana Laboratories S.A., Cosmos Health maintains high standards under European Good Manufacturing Practices (GMP) and holds certification from the European Medicines Agency (EMA).
Global Distribution and R&D
Cosmos Health doesn’t stop at manufacturing. The company actively distributes a wide range of pharmaceuticals to retail pharmacies and wholesale distributors across the UK and Greece. Moreover, it is making strides in research and development, forming partnerships aimed at combating significant health issues such as obesity, diabetes, and cancer. Utilizing advanced artificial intelligence technologies, the company is focusing on creating novel patented nutraceuticals and specialized products.
Expansion into Telehealth
In recent developments, Cosmos Health has ventured into the telehealth arena through the acquisition of ZipDoctor, enhancing its healthcare service offerings and broadening its reach across the market. This strategic move positions the company well in an ever-evolving healthcare landscape, aiming to meet the growing desire for accessible healthcare solutions.
Contact Information
For those interested in further discussions or inquiries, Cosmos Health’s investor relations can be reached through BDG Communications at cosm@bdgcommunications.com or via phone at +44 207 0971 653.
Frequently Asked Questions
1. What has Greg Siokas recently acquired?
Greg Siokas has acquired 1,466,764 shares, valued at $526,000, increasing his stake in Cosmos Health significantly.
2. How much has Siokas invested over the past five months?
He has invested over $1.3 million during this period, enhancing his ownership of the company.
3. How many total shares does Siokas own in Cosmos Health?
After his recent acquisitions, Siokas now owns a total of 5,582,066 shares in Cosmos Health.
4. What innovations is Cosmos Health focused on?
The company is actively developing pharmaceuticals for major health issues and entering new markets, including telehealth.
5. Where can I find more information about Cosmos Health?
You can visit their official website for detailed insights into the company's products and services.
